WHO ICTRP trial
In-vivo Bioequivalence Test of Ibuprofen tablet 800 mg Mofid Pharma with brand…
IRCT20200105046010N67 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20200105046010N67 |
|---|---|
| Public title | In-vivo Bioequivalence Test of Ibuprofen tablet 800 mg Mofid Pharma with brand drug (BRUFEN® ER. 800 mg Tab, Mylan, Germany) |
| Scientific title | In- Vivo Bioequivalence study of Ibuprofen tablet 800 mg Mofid Pharma (DRASTIFEN® ER. 800 mgTab, Mofid Pharma, Iran) with brand drugs (BRUFEN® ER. 800 mg Tab, Mylan, Germany) in Iranian healthy volunteers. |
| Primary sponsor | Teb Mofid Nikan Pharmaceutical Co. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Bio equivalence test. |
| Interventions | Intervention 1: Intervention group: One test tablet (Ibuprofen tablet 800 mg Mofid Pharma) will be received. Blood samples will be taken for 48 hours at the mentioned times after drug administration and the concentration of the drug in… |
| Registration date | Sep 4, 2022 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: